TY - JOUR
T1 - Reversible conformational change in the plasmodium falciparum circumsporozoite protein masks Its adhesion domains
AU - Herrera, Raul
AU - Anderson, Charles
AU - Kumar, Krishan
AU - Molina-Cruz, Alvaro
AU - Nguyen, Vu
AU - Burkhardt, Martin
AU - Reiter, Karine
AU - Shimp, Richard
AU - Howard, Randall F.
AU - Srinivasan, Prakash
AU - Nold, Michael J.
AU - Ragheb, Daniel
AU - Shi, Lirong
AU - DeCotiis, Mark
AU - Aebig, Joan
AU - Lambert, Lynn
AU - Rausch, Kelly M.
AU - Muratova, Olga
AU - Jin, Albert
AU - Reed, Steven G.
AU - Sinnis, Photini
AU - Barillas-Mury, Carolina
AU - Duffy, Patrick E.
AU - MacDonald, Nicholas J.
AU - Naruma, David L.
N1 - Publisher Copyright:
© 2015, American Society for Microbiology.
PY - 2015
Y1 - 2015
N2 - The extended rod-like Plasmodium falciparum circumsporozoite protein (CSP) is comprised of three primary domains: a charged N terminus that binds heparan sulfate proteoglycans, a central NANP repeat domain, and a C terminus containing a thrombospondin-like type I repeat (TSR) domain. Only the last two domains are incorporated in RTS, S, the leading malaria vaccine in phase 3 trials that, to date, protects about 50% of vaccinated children against clinical disease. A eroepidemiological study indicated that the N-terminal domain might improve the efficacy of a new CSP vaccine. Using a panel of CSP-specific monoclonal antibodies, well-characterized recombinant CSPs, label-free quantitative proteomics, and in vitro inhibition of sporozoite invasion, we show that native CSP is N-terminally processed in the mosquito host and undergoes a reversible conformational change to mask some epitopes in the N- and C-terminal domains until the sporozoite interacts with the liver hepatocyte. Our findings show the importance of understanding processing and the biophysical change in conformation, possibly due to a mechanical or molecular signal, and may aid in the development of a new CSP vaccine.
AB - The extended rod-like Plasmodium falciparum circumsporozoite protein (CSP) is comprised of three primary domains: a charged N terminus that binds heparan sulfate proteoglycans, a central NANP repeat domain, and a C terminus containing a thrombospondin-like type I repeat (TSR) domain. Only the last two domains are incorporated in RTS, S, the leading malaria vaccine in phase 3 trials that, to date, protects about 50% of vaccinated children against clinical disease. A eroepidemiological study indicated that the N-terminal domain might improve the efficacy of a new CSP vaccine. Using a panel of CSP-specific monoclonal antibodies, well-characterized recombinant CSPs, label-free quantitative proteomics, and in vitro inhibition of sporozoite invasion, we show that native CSP is N-terminally processed in the mosquito host and undergoes a reversible conformational change to mask some epitopes in the N- and C-terminal domains until the sporozoite interacts with the liver hepatocyte. Our findings show the importance of understanding processing and the biophysical change in conformation, possibly due to a mechanical or molecular signal, and may aid in the development of a new CSP vaccine.
UR - http://www.scopus.com/inward/record.url?scp=84944463567&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84944463567&partnerID=8YFLogxK
U2 - 10.1128/IAI.02676-14
DO - 10.1128/IAI.02676-14
M3 - Article
C2 - 26169272
AN - SCOPUS:84944463567
SN - 0019-9567
VL - 83
SP - 3771
EP - 3780
JO - Infection and Immunity
JF - Infection and Immunity
IS - 10
ER -